Global Orally Disintegrating Tablet

Orally Disintegrating Tablet Comprehensive Study by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Stores, Online Pharmacy), Manufacturing Technique (Conventional techniques, Patented techniques), Drug Class (Anti-Psychotic, Anti-Epileptic’s, CNS Stimulants, Anxiolytics, Anti-Parkinson Ian Drugs, Anti-Hypertensive, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitor, Others), Disease Indication (Central Nervous System Diseases (CNS), Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, Others) Players and Region - Global Market Outlook to 2026

Orally Disintegrating Tablet Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 10.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Orally Disintegrating Tablet Market Scope
An orally disintegrating tablet is a drug dosage form available for a limited range of over-the-counter and prescription medications. It differs from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. ODTs dissolve or disintegrate in the mouth without water within sixty seconds when placed on the patient's tongue. They're ideal for patients such as older adults or children who have difficulty swallowing traditional oral capsules or tablets and those with mental illness.

According to AMA, the Global Orally Disintegrating Tablet market is expected to see growth rate of 10.7%

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Orally Disintegrating Tablet market throughout the predicted period.

Janssen Pharmaceutica (Belgium), Schering plough Corp., USA (United States), Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Bayer AG (Germany), Pfizer (United States), Merck & Co. (United States), Eli Lilly Pharma (United States), GlaxoSmithKline (United Kingdom), Ranbaxy Laboratories (India), Astra Zeneca (United Kingdom), Takeda Pharmaceutical Company Limited (Japan) and Zota Pharma (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Torrent Group (India), Mylan N.V. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Bausch Health (Canada), Sun Pharmaceutical Industries Ltd. (India), Dr. Reddy’s Laboratories Ltd (India), Eisai Co., Ltd. (Japan), NEOS Therapeutics, Inc. (Switzerland), Glenmark Pharmaceuticals (India) and Unichem Laboratories (India).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Orally Disintegrating Tablet market and Region with country level break-up.

On the basis of geography, the market of Orally Disintegrating Tablet has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
Neos Therapeutics, Inc., announced that it has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA, Inc. to resolve all ongoing litigation involving Neos' patents protecting its Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets and Teva's Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration to market a generic version of that product.
Global pharmaceutical company Mylan N.V. announced the U.S. launch of Lansoprazole Delayed-Release (DR) Orally Disintegrating Tablets (ODT), 15 mg and 30 mg, a generic version of Takeda's Prevacid SoluTab DR ODT. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which has the same indications as the reference listed drug, including treatment of active ulcers of the stomach and small intestine, gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. and On 8 June 2017, Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (od tablet:orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin), will be launched on June 8.


Market Drivers
  • The Rising Geriatric Population Worldwide
  • Increasing Number of Mentally Challenged People
  • The Advantages Offered by the Orally Disintegrating Drugs

Opportunities
  • The emergence of Next Generation ODTs
  • The Emerging Demand from Developing Countries

Restraints
  • The High Cost of the Production

Challenges
  • Mechanical strength and disintegration time
  • Taste masking


Key Target Audience
Orally Disintegrating Drugs Manufacturers, Orally Disintegrating Drugs Traders/Distributors, Orally Disintegrating Drugs Importer/Exporter, Regulatory & Government Bodies, Research & Consulting Firms, End Users and Others

Report Objectives / Segmentation Covered

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Stores
  • Online Pharmacy

By Manufacturing Technique
  • Conventional techniques
  • Patented techniques

By Drug Class
  • Anti-Psychotic
  • Anti-Epileptic’s
  • CNS Stimulants
  • Anxiolytics
  • Anti-Parkinson Ian Drugs
  • Anti-Hypertensive
  • NSAIDS
  • Anti-Allergy Drugs
  • Proton Pump Inhibitor
  • Others

By Disease Indication
  • Central Nervous System Diseases (CNS)
  • Gastrointestinal (GI) Diseases
  • Cardiovascular (CVS) Diseases
  • Allergy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Geriatric Population Worldwide
      • 3.2.2. Increasing Number of Mentally Challenged People
      • 3.2.3. The Advantages Offered by the Orally Disintegrating Drugs
    • 3.3. Market Challenges
      • 3.3.1. Mechanical strength and disintegration time
      • 3.3.2. Taste masking
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Orally Disintegrating Tablet, by Distribution Channel, Manufacturing Technique, Drug Class, Disease Indication and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Orally Disintegrating Tablet (Value)
      • 5.2.1. Global Orally Disintegrating Tablet by: Distribution Channel (Value)
        • 5.2.1.1. Hospital Pharmacy
        • 5.2.1.2. Retail Pharmacy
        • 5.2.1.3. Drug Stores
        • 5.2.1.4. Online Pharmacy
      • 5.2.2. Global Orally Disintegrating Tablet by: Manufacturing Technique (Value)
        • 5.2.2.1. Conventional techniques
        • 5.2.2.2. Patented techniques
      • 5.2.3. Global Orally Disintegrating Tablet by: Drug Class (Value)
        • 5.2.3.1. Anti-Psychotic
        • 5.2.3.2. Anti-Epileptic’s
        • 5.2.3.3. CNS Stimulants
        • 5.2.3.4. Anxiolytics
        • 5.2.3.5. Anti-Parkinson Ian Drugs
        • 5.2.3.6. Anti-Hypertensive
        • 5.2.3.7. NSAIDS
        • 5.2.3.8. Anti-Allergy Drugs
        • 5.2.3.9. Proton Pump Inhibitor
        • 5.2.3.10. Others
      • 5.2.4. Global Orally Disintegrating Tablet by: Disease Indication (Value)
        • 5.2.4.1. Central Nervous System Diseases (CNS)
        • 5.2.4.2. Gastrointestinal (GI) Diseases
        • 5.2.4.3. Cardiovascular (CVS) Diseases
        • 5.2.4.4. Allergy
        • 5.2.4.5. Others
      • 5.2.5. Global Orally Disintegrating Tablet Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Orally Disintegrating Tablet (Volume)
      • 5.3.1. Global Orally Disintegrating Tablet by: Distribution Channel (Volume)
        • 5.3.1.1. Hospital Pharmacy
        • 5.3.1.2. Retail Pharmacy
        • 5.3.1.3. Drug Stores
        • 5.3.1.4. Online Pharmacy
      • 5.3.2. Global Orally Disintegrating Tablet by: Manufacturing Technique (Volume)
        • 5.3.2.1. Conventional techniques
        • 5.3.2.2. Patented techniques
      • 5.3.3. Global Orally Disintegrating Tablet by: Drug Class (Volume)
        • 5.3.3.1. Anti-Psychotic
        • 5.3.3.2. Anti-Epileptic’s
        • 5.3.3.3. CNS Stimulants
        • 5.3.3.4. Anxiolytics
        • 5.3.3.5. Anti-Parkinson Ian Drugs
        • 5.3.3.6. Anti-Hypertensive
        • 5.3.3.7. NSAIDS
        • 5.3.3.8. Anti-Allergy Drugs
        • 5.3.3.9. Proton Pump Inhibitor
        • 5.3.3.10. Others
      • 5.3.4. Global Orally Disintegrating Tablet by: Disease Indication (Volume)
        • 5.3.4.1. Central Nervous System Diseases (CNS)
        • 5.3.4.2. Gastrointestinal (GI) Diseases
        • 5.3.4.3. Cardiovascular (CVS) Diseases
        • 5.3.4.4. Allergy
        • 5.3.4.5. Others
      • 5.3.5. Global Orally Disintegrating Tablet Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Orally Disintegrating Tablet (Price)
  • 6. Orally Disintegrating Tablet: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Janssen Pharmaceutica (Belgium)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Schering plough Corp., USA (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly Pharma (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ranbaxy Laboratories (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Astra Zeneca (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Zota Pharma (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Orally Disintegrating Tablet Sale, by Distribution Channel, Manufacturing Technique, Drug Class, Disease Indication and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Orally Disintegrating Tablet (Value)
      • 7.2.1. Global Orally Disintegrating Tablet by: Distribution Channel (Value)
        • 7.2.1.1. Hospital Pharmacy
        • 7.2.1.2. Retail Pharmacy
        • 7.2.1.3. Drug Stores
        • 7.2.1.4. Online Pharmacy
      • 7.2.2. Global Orally Disintegrating Tablet by: Manufacturing Technique (Value)
        • 7.2.2.1. Conventional techniques
        • 7.2.2.2. Patented techniques
      • 7.2.3. Global Orally Disintegrating Tablet by: Drug Class (Value)
        • 7.2.3.1. Anti-Psychotic
        • 7.2.3.2. Anti-Epileptic’s
        • 7.2.3.3. CNS Stimulants
        • 7.2.3.4. Anxiolytics
        • 7.2.3.5. Anti-Parkinson Ian Drugs
        • 7.2.3.6. Anti-Hypertensive
        • 7.2.3.7. NSAIDS
        • 7.2.3.8. Anti-Allergy Drugs
        • 7.2.3.9. Proton Pump Inhibitor
        • 7.2.3.10. Others
      • 7.2.4. Global Orally Disintegrating Tablet by: Disease Indication (Value)
        • 7.2.4.1. Central Nervous System Diseases (CNS)
        • 7.2.4.2. Gastrointestinal (GI) Diseases
        • 7.2.4.3. Cardiovascular (CVS) Diseases
        • 7.2.4.4. Allergy
        • 7.2.4.5. Others
      • 7.2.5. Global Orally Disintegrating Tablet Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Orally Disintegrating Tablet (Volume)
      • 7.3.1. Global Orally Disintegrating Tablet by: Distribution Channel (Volume)
        • 7.3.1.1. Hospital Pharmacy
        • 7.3.1.2. Retail Pharmacy
        • 7.3.1.3. Drug Stores
        • 7.3.1.4. Online Pharmacy
      • 7.3.2. Global Orally Disintegrating Tablet by: Manufacturing Technique (Volume)
        • 7.3.2.1. Conventional techniques
        • 7.3.2.2. Patented techniques
      • 7.3.3. Global Orally Disintegrating Tablet by: Drug Class (Volume)
        • 7.3.3.1. Anti-Psychotic
        • 7.3.3.2. Anti-Epileptic’s
        • 7.3.3.3. CNS Stimulants
        • 7.3.3.4. Anxiolytics
        • 7.3.3.5. Anti-Parkinson Ian Drugs
        • 7.3.3.6. Anti-Hypertensive
        • 7.3.3.7. NSAIDS
        • 7.3.3.8. Anti-Allergy Drugs
        • 7.3.3.9. Proton Pump Inhibitor
        • 7.3.3.10. Others
      • 7.3.4. Global Orally Disintegrating Tablet by: Disease Indication (Volume)
        • 7.3.4.1. Central Nervous System Diseases (CNS)
        • 7.3.4.2. Gastrointestinal (GI) Diseases
        • 7.3.4.3. Cardiovascular (CVS) Diseases
        • 7.3.4.4. Allergy
        • 7.3.4.5. Others
      • 7.3.5. Global Orally Disintegrating Tablet Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Orally Disintegrating Tablet (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Orally Disintegrating Tablet: by Distribution Channel(USD Million)
  • Figure 4. Global Orally Disintegrating Tablet: by Distribution Channel USD Million (2015-2020)
  • Table 2. Orally Disintegrating Tablet Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 3. Orally Disintegrating Tablet Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 4. Orally Disintegrating Tablet Drug Stores , by Region USD Million (2015-2020)
  • Table 5. Orally Disintegrating Tablet Online Pharmacy , by Region USD Million (2015-2020)
  • Table 6. Orally Disintegrating Tablet: by Manufacturing Technique(USD Million)
  • Figure 5. Global Orally Disintegrating Tablet: by Manufacturing Technique USD Million (2015-2020)
  • Table 7. Orally Disintegrating Tablet Conventional techniques , by Region USD Million (2015-2020)
  • Table 8. Orally Disintegrating Tablet Patented techniques , by Region USD Million (2015-2020)
  • Table 9. Orally Disintegrating Tablet: by Drug Class(USD Million)
  • Figure 6. Global Orally Disintegrating Tablet: by Drug Class USD Million (2015-2020)
  • Table 10. Orally Disintegrating Tablet Anti-Psychotic , by Region USD Million (2015-2020)
  • Table 11. Orally Disintegrating Tablet Anti-Epileptic’s , by Region USD Million (2015-2020)
  • Table 12. Orally Disintegrating Tablet CNS Stimulants , by Region USD Million (2015-2020)
  • Table 13. Orally Disintegrating Tablet Anxiolytics , by Region USD Million (2015-2020)
  • Table 14. Orally Disintegrating Tablet Anti-Parkinson Ian Drugs , by Region USD Million (2015-2020)
  • Table 15. Orally Disintegrating Tablet Anti-Hypertensive , by Region USD Million (2015-2020)
  • Table 16. Orally Disintegrating Tablet NSAIDS , by Region USD Million (2015-2020)
  • Table 17. Orally Disintegrating Tablet Anti-Allergy Drugs , by Region USD Million (2015-2020)
  • Table 18. Orally Disintegrating Tablet Proton Pump Inhibitor , by Region USD Million (2015-2020)
  • Table 19. Orally Disintegrating Tablet Others , by Region USD Million (2015-2020)
  • Table 20. Orally Disintegrating Tablet: by Disease Indication(USD Million)
  • Figure 7. Global Orally Disintegrating Tablet: by Disease Indication USD Million (2015-2020)
  • Table 21. Orally Disintegrating Tablet Central Nervous System Diseases (CNS) , by Region USD Million (2015-2020)
  • Table 22. Orally Disintegrating Tablet Gastrointestinal (GI) Diseases , by Region USD Million (2015-2020)
  • Table 23. Orally Disintegrating Tablet Cardiovascular (CVS) Diseases , by Region USD Million (2015-2020)
  • Table 24. Orally Disintegrating Tablet Allergy , by Region USD Million (2015-2020)
  • Table 25. Orally Disintegrating Tablet Others , by Region USD Million (2015-2020)
  • Table 26. South America Orally Disintegrating Tablet, by Country USD Million (2015-2020)
  • Figure 8. South America Orally Disintegrating Tablet Share (%), by Country
  • Table 27. South America Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 28. South America Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 29. South America Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 30. South America Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 31. Brazil Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 32. Brazil Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 33. Brazil Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 34. Brazil Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 35. Argentina Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 36. Argentina Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 37. Argentina Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 38. Argentina Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 39. Rest of South America Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 40. Rest of South America Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 41. Rest of South America Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 42. Rest of South America Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 43. Asia Pacific Orally Disintegrating Tablet, by Country USD Million (2015-2020)
  • Figure 9. Asia Pacific Orally Disintegrating Tablet Share (%), by Country
  • Table 44. Asia Pacific Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 45. Asia Pacific Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 46. Asia Pacific Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 47. Asia Pacific Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 48. China Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 49. China Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 50. China Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 51. China Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 52. Japan Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 53. Japan Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 54. Japan Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 55. Japan Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 56. India Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 57. India Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 58. India Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 59. India Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 60. South Korea Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 61. South Korea Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 62. South Korea Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 63. South Korea Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 64. Taiwan Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 65. Taiwan Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 66. Taiwan Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 67. Taiwan Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 68. Australia Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 69. Australia Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 70. Australia Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 71. Australia Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 76. Europe Orally Disintegrating Tablet, by Country USD Million (2015-2020)
  • Figure 10. Europe Orally Disintegrating Tablet Share (%), by Country
  • Table 77. Europe Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 78. Europe Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 79. Europe Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 80. Europe Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 81. Germany Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 82. Germany Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 83. Germany Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 84. Germany Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 85. France Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 86. France Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 87. France Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 88. France Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 89. Italy Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 90. Italy Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 91. Italy Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 92. Italy Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 93. United Kingdom Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 94. United Kingdom Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 95. United Kingdom Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 96. United Kingdom Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 97. Netherlands Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 98. Netherlands Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 99. Netherlands Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 100. Netherlands Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 101. Rest of Europe Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 102. Rest of Europe Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 103. Rest of Europe Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 104. Rest of Europe Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 105. MEA Orally Disintegrating Tablet, by Country USD Million (2015-2020)
  • Figure 11. MEA Orally Disintegrating Tablet Share (%), by Country
  • Table 106. MEA Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 107. MEA Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 108. MEA Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 109. MEA Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 110. Middle East Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 111. Middle East Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 112. Middle East Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 113. Middle East Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 114. Africa Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 115. Africa Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 116. Africa Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 117. Africa Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 118. North America Orally Disintegrating Tablet, by Country USD Million (2015-2020)
  • Figure 12. North America Orally Disintegrating Tablet Share (%), by Country
  • Table 119. North America Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 120. North America Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 121. North America Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 122. North America Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 123. United States Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 124. United States Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 125. United States Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 126. United States Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 127. Canada Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 128. Canada Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 129. Canada Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 130. Canada Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 131. Mexico Orally Disintegrating Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 132. Mexico Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2015-2020)
  • Table 133. Mexico Orally Disintegrating Tablet, by Drug Class USD Million (2015-2020)
  • Table 134. Mexico Orally Disintegrating Tablet, by Disease Indication USD Million (2015-2020)
  • Table 135. Orally Disintegrating Tablet Sales: by Distribution Channel(K Tons)
  • Figure 13. Global Orally Disintegrating Tablet: by Distribution Channel K Tons (2015-2020)
  • Table 136. Orally Disintegrating Tablet Sales Hospital Pharmacy , by Region K Tons (2015-2020)
  • Table 137. Orally Disintegrating Tablet Sales Retail Pharmacy , by Region K Tons (2015-2020)
  • Table 138. Orally Disintegrating Tablet Sales Drug Stores , by Region K Tons (2015-2020)
  • Table 139. Orally Disintegrating Tablet Sales Online Pharmacy , by Region K Tons (2015-2020)
  • Table 140. Orally Disintegrating Tablet Sales: by Manufacturing Technique(K Tons)
  • Figure 14. Global Orally Disintegrating Tablet: by Manufacturing Technique K Tons (2015-2020)
  • Table 141. Orally Disintegrating Tablet Sales Conventional techniques , by Region K Tons (2015-2020)
  • Table 142. Orally Disintegrating Tablet Sales Patented techniques , by Region K Tons (2015-2020)
  • Table 143. Orally Disintegrating Tablet Sales: by Drug Class(K Tons)
  • Figure 15. Global Orally Disintegrating Tablet: by Drug Class K Tons (2015-2020)
  • Table 144. Orally Disintegrating Tablet Sales Anti-Psychotic , by Region K Tons (2015-2020)
  • Table 145. Orally Disintegrating Tablet Sales Anti-Epileptic’s , by Region K Tons (2015-2020)
  • Table 146. Orally Disintegrating Tablet Sales CNS Stimulants , by Region K Tons (2015-2020)
  • Table 147. Orally Disintegrating Tablet Sales Anxiolytics , by Region K Tons (2015-2020)
  • Table 148. Orally Disintegrating Tablet Sales Anti-Parkinson Ian Drugs , by Region K Tons (2015-2020)
  • Table 149. Orally Disintegrating Tablet Sales Anti-Hypertensive , by Region K Tons (2015-2020)
  • Table 150. Orally Disintegrating Tablet Sales NSAIDS , by Region K Tons (2015-2020)
  • Table 151. Orally Disintegrating Tablet Sales Anti-Allergy Drugs , by Region K Tons (2015-2020)
  • Table 152. Orally Disintegrating Tablet Sales Proton Pump Inhibitor , by Region K Tons (2015-2020)
  • Table 153. Orally Disintegrating Tablet Sales Others , by Region K Tons (2015-2020)
  • Table 154. Orally Disintegrating Tablet Sales: by Disease Indication(K Tons)
  • Figure 16. Global Orally Disintegrating Tablet: by Disease Indication K Tons (2015-2020)
  • Table 155. Orally Disintegrating Tablet Sales Central Nervous System Diseases (CNS) , by Region K Tons (2015-2020)
  • Table 156. Orally Disintegrating Tablet Sales Gastrointestinal (GI) Diseases , by Region K Tons (2015-2020)
  • Table 157. Orally Disintegrating Tablet Sales Cardiovascular (CVS) Diseases , by Region K Tons (2015-2020)
  • Table 158. Orally Disintegrating Tablet Sales Allergy , by Region K Tons (2015-2020)
  • Table 159. Orally Disintegrating Tablet Sales Others , by Region K Tons (2015-2020)
  • Table 160. South America Orally Disintegrating Tablet Sales, by Country K Tons (2015-2020)
  • Figure 17. South America Orally Disintegrating Tablet Share (%), by Country
  • Table 161. South America Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 162. South America Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 163. South America Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 164. South America Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 165. Brazil Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 166. Brazil Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 167. Brazil Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 168. Brazil Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 169. Argentina Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 170. Argentina Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 171. Argentina Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 172. Argentina Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 173. Rest of South America Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 174. Rest of South America Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 175. Rest of South America Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 176. Rest of South America Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 177. Asia Pacific Orally Disintegrating Tablet Sales, by Country K Tons (2015-2020)
  • Figure 18. Asia Pacific Orally Disintegrating Tablet Share (%), by Country
  • Table 178. Asia Pacific Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 179. Asia Pacific Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 180. Asia Pacific Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 181. Asia Pacific Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 182. China Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 183. China Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 184. China Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 185. China Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 186. Japan Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 187. Japan Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 188. Japan Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 189. Japan Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 190. India Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 191. India Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 192. India Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 193. India Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 194. South Korea Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 195. South Korea Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 196. South Korea Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 197. South Korea Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 198. Taiwan Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 199. Taiwan Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 200. Taiwan Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 201. Taiwan Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 202. Australia Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 203. Australia Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 204. Australia Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 205. Australia Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 206. Rest of Asia-Pacific Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 207. Rest of Asia-Pacific Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 208. Rest of Asia-Pacific Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 209. Rest of Asia-Pacific Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 210. Europe Orally Disintegrating Tablet Sales, by Country K Tons (2015-2020)
  • Figure 19. Europe Orally Disintegrating Tablet Share (%), by Country
  • Table 211. Europe Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 212. Europe Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 213. Europe Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 214. Europe Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 215. Germany Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 216. Germany Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 217. Germany Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 218. Germany Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 219. France Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 220. France Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 221. France Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 222. France Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 223. Italy Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 224. Italy Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 225. Italy Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 226. Italy Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 227. United Kingdom Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 228. United Kingdom Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 229. United Kingdom Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 230. United Kingdom Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 231. Netherlands Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 232. Netherlands Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 233. Netherlands Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 234. Netherlands Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 235. Rest of Europe Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 236. Rest of Europe Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 237. Rest of Europe Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 238. Rest of Europe Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 239. MEA Orally Disintegrating Tablet Sales, by Country K Tons (2015-2020)
  • Figure 20. MEA Orally Disintegrating Tablet Share (%), by Country
  • Table 240. MEA Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 241. MEA Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 242. MEA Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 243. MEA Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 244. Middle East Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 245. Middle East Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 246. Middle East Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 247. Middle East Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 248. Africa Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 249. Africa Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 250. Africa Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 251. Africa Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 252. North America Orally Disintegrating Tablet Sales, by Country K Tons (2015-2020)
  • Figure 21. North America Orally Disintegrating Tablet Share (%), by Country
  • Table 253. North America Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 254. North America Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 255. North America Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 256. North America Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 257. United States Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 258. United States Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 259. United States Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 260. United States Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 261. Canada Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 262. Canada Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 263. Canada Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 264. Canada Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Table 265. Mexico Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2015-2020)
  • Table 266. Mexico Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2015-2020)
  • Table 267. Mexico Orally Disintegrating Tablet Sales, by Drug Class K Tons (2015-2020)
  • Table 268. Mexico Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2015-2020)
  • Figure 22. Global Orally Disintegrating Tablet share by Players 2020 (%)
  • Figure 23. Global Orally Disintegrating Tablet share by Players (Top 3) 2020(%)
  • Figure 24. Global Orally Disintegrating Tablet share by Players (Top 5) 2020(%)
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Company Basic Information, Sales Area and Its Competitors
  • Table 276. Company Basic Information, Sales Area and Its Competitors
  • Table 277. Company Basic Information, Sales Area and Its Competitors
  • Table 278. Company Basic Information, Sales Area and Its Competitors
  • Table 279. Company Basic Information, Sales Area and Its Competitors
  • Table 280. Company Basic Information, Sales Area and Its Competitors
  • Table 281. Company Basic Information, Sales Area and Its Competitors
  • Table 282. Orally Disintegrating Tablet: by Distribution Channel(USD Million)
  • Figure 52. Global Orally Disintegrating Tablet: by Distribution Channel USD Million (2021-2026)
  • Table 283. Orally Disintegrating Tablet Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 284. Orally Disintegrating Tablet Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 285. Orally Disintegrating Tablet Drug Stores , by Region USD Million (2021-2026)
  • Table 286. Orally Disintegrating Tablet Online Pharmacy , by Region USD Million (2021-2026)
  • Table 287. Orally Disintegrating Tablet: by Manufacturing Technique(USD Million)
  • Figure 53. Global Orally Disintegrating Tablet: by Manufacturing Technique USD Million (2021-2026)
  • Table 288. Orally Disintegrating Tablet Conventional techniques , by Region USD Million (2021-2026)
  • Table 289. Orally Disintegrating Tablet Patented techniques , by Region USD Million (2021-2026)
  • Table 290. Orally Disintegrating Tablet: by Drug Class(USD Million)
  • Figure 54. Global Orally Disintegrating Tablet: by Drug Class USD Million (2021-2026)
  • Table 291. Orally Disintegrating Tablet Anti-Psychotic , by Region USD Million (2021-2026)
  • Table 292. Orally Disintegrating Tablet Anti-Epileptic’s , by Region USD Million (2021-2026)
  • Table 293. Orally Disintegrating Tablet CNS Stimulants , by Region USD Million (2021-2026)
  • Table 294. Orally Disintegrating Tablet Anxiolytics , by Region USD Million (2021-2026)
  • Table 295. Orally Disintegrating Tablet Anti-Parkinson Ian Drugs , by Region USD Million (2021-2026)
  • Table 296. Orally Disintegrating Tablet Anti-Hypertensive , by Region USD Million (2021-2026)
  • Table 297. Orally Disintegrating Tablet NSAIDS , by Region USD Million (2021-2026)
  • Table 298. Orally Disintegrating Tablet Anti-Allergy Drugs , by Region USD Million (2021-2026)
  • Table 299. Orally Disintegrating Tablet Proton Pump Inhibitor , by Region USD Million (2021-2026)
  • Table 300. Orally Disintegrating Tablet Others , by Region USD Million (2021-2026)
  • Table 301. Orally Disintegrating Tablet: by Disease Indication(USD Million)
  • Figure 55. Global Orally Disintegrating Tablet: by Disease Indication USD Million (2021-2026)
  • Table 302. Orally Disintegrating Tablet Central Nervous System Diseases (CNS) , by Region USD Million (2021-2026)
  • Table 303. Orally Disintegrating Tablet Gastrointestinal (GI) Diseases , by Region USD Million (2021-2026)
  • Table 304. Orally Disintegrating Tablet Cardiovascular (CVS) Diseases , by Region USD Million (2021-2026)
  • Table 305. Orally Disintegrating Tablet Allergy , by Region USD Million (2021-2026)
  • Table 306. Orally Disintegrating Tablet Others , by Region USD Million (2021-2026)
  • Table 307. South America Orally Disintegrating Tablet, by Country USD Million (2021-2026)
  • Figure 56. South America Orally Disintegrating Tablet Share (%), by Country
  • Table 308. South America Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 309. South America Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 310. South America Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 311. South America Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 312. Brazil Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 313. Brazil Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 314. Brazil Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 315. Brazil Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 316. Argentina Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 317. Argentina Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 318. Argentina Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 319. Argentina Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 320. Rest of South America Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 321. Rest of South America Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 322. Rest of South America Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 323. Rest of South America Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 324. Asia Pacific Orally Disintegrating Tablet, by Country USD Million (2021-2026)
  • Figure 57. Asia Pacific Orally Disintegrating Tablet Share (%), by Country
  • Table 325. Asia Pacific Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 326. Asia Pacific Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 327. Asia Pacific Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 328. Asia Pacific Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 329. China Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 330. China Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 331. China Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 332. China Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 333. Japan Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 334. Japan Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 335. Japan Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 336. Japan Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 337. India Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 338. India Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 339. India Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 340. India Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 341. South Korea Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 342. South Korea Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 343. South Korea Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 344. South Korea Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 345. Taiwan Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 346. Taiwan Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 347. Taiwan Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 348. Taiwan Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 349. Australia Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 350. Australia Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 351. Australia Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 352. Australia Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 353. Rest of Asia-Pacific Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 354. Rest of Asia-Pacific Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 355. Rest of Asia-Pacific Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 356. Rest of Asia-Pacific Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 357. Europe Orally Disintegrating Tablet, by Country USD Million (2021-2026)
  • Figure 58. Europe Orally Disintegrating Tablet Share (%), by Country
  • Table 358. Europe Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 359. Europe Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 360. Europe Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 361. Europe Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 362. Germany Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 363. Germany Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 364. Germany Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 365. Germany Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 366. France Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 367. France Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 368. France Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 369. France Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 370. Italy Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 371. Italy Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 372. Italy Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 373. Italy Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 374. United Kingdom Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 375. United Kingdom Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 376. United Kingdom Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 377. United Kingdom Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 378. Netherlands Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 379. Netherlands Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 380. Netherlands Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 381. Netherlands Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 382. Rest of Europe Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 383. Rest of Europe Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 384. Rest of Europe Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 385. Rest of Europe Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 386. MEA Orally Disintegrating Tablet, by Country USD Million (2021-2026)
  • Figure 59. MEA Orally Disintegrating Tablet Share (%), by Country
  • Table 387. MEA Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 388. MEA Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 389. MEA Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 390. MEA Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 391. Middle East Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 392. Middle East Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 393. Middle East Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 394. Middle East Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 395. Africa Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 396. Africa Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 397. Africa Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 398. Africa Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 399. North America Orally Disintegrating Tablet, by Country USD Million (2021-2026)
  • Figure 60. North America Orally Disintegrating Tablet Share (%), by Country
  • Table 400. North America Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 401. North America Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 402. North America Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 403. North America Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 404. United States Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 405. United States Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 406. United States Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 407. United States Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 408. Canada Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 409. Canada Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 410. Canada Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 411. Canada Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 412. Mexico Orally Disintegrating Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 413. Mexico Orally Disintegrating Tablet, by Manufacturing Technique USD Million (2021-2026)
  • Table 414. Mexico Orally Disintegrating Tablet, by Drug Class USD Million (2021-2026)
  • Table 415. Mexico Orally Disintegrating Tablet, by Disease Indication USD Million (2021-2026)
  • Table 416. Orally Disintegrating Tablet Sales: by Distribution Channel(K Tons)
  • Figure 61. Global Orally Disintegrating Tablet: by Distribution Channel K Tons (2021-2026)
  • Table 417. Orally Disintegrating Tablet Sales Hospital Pharmacy , by Region K Tons (2021-2026)
  • Table 418. Orally Disintegrating Tablet Sales Retail Pharmacy , by Region K Tons (2021-2026)
  • Table 419. Orally Disintegrating Tablet Sales Drug Stores , by Region K Tons (2021-2026)
  • Table 420. Orally Disintegrating Tablet Sales Online Pharmacy , by Region K Tons (2021-2026)
  • Table 421. Orally Disintegrating Tablet Sales: by Manufacturing Technique(K Tons)
  • Figure 62. Global Orally Disintegrating Tablet: by Manufacturing Technique K Tons (2021-2026)
  • Table 422. Orally Disintegrating Tablet Sales Conventional techniques , by Region K Tons (2021-2026)
  • Table 423. Orally Disintegrating Tablet Sales Patented techniques , by Region K Tons (2021-2026)
  • Table 424. Orally Disintegrating Tablet Sales: by Drug Class(K Tons)
  • Figure 63. Global Orally Disintegrating Tablet: by Drug Class K Tons (2021-2026)
  • Table 425. Orally Disintegrating Tablet Sales Anti-Psychotic , by Region K Tons (2021-2026)
  • Table 426. Orally Disintegrating Tablet Sales Anti-Epileptic’s , by Region K Tons (2021-2026)
  • Table 427. Orally Disintegrating Tablet Sales CNS Stimulants , by Region K Tons (2021-2026)
  • Table 428. Orally Disintegrating Tablet Sales Anxiolytics , by Region K Tons (2021-2026)
  • Table 429. Orally Disintegrating Tablet Sales Anti-Parkinson Ian Drugs , by Region K Tons (2021-2026)
  • Table 430. Orally Disintegrating Tablet Sales Anti-Hypertensive , by Region K Tons (2021-2026)
  • Table 431. Orally Disintegrating Tablet Sales NSAIDS , by Region K Tons (2021-2026)
  • Table 432. Orally Disintegrating Tablet Sales Anti-Allergy Drugs , by Region K Tons (2021-2026)
  • Table 433. Orally Disintegrating Tablet Sales Proton Pump Inhibitor , by Region K Tons (2021-2026)
  • Table 434. Orally Disintegrating Tablet Sales Others , by Region K Tons (2021-2026)
  • Table 435. Orally Disintegrating Tablet Sales: by Disease Indication(K Tons)
  • Figure 64. Global Orally Disintegrating Tablet: by Disease Indication K Tons (2021-2026)
  • Table 436. Orally Disintegrating Tablet Sales Central Nervous System Diseases (CNS) , by Region K Tons (2021-2026)
  • Table 437. Orally Disintegrating Tablet Sales Gastrointestinal (GI) Diseases , by Region K Tons (2021-2026)
  • Table 438. Orally Disintegrating Tablet Sales Cardiovascular (CVS) Diseases , by Region K Tons (2021-2026)
  • Table 439. Orally Disintegrating Tablet Sales Allergy , by Region K Tons (2021-2026)
  • Table 440. Orally Disintegrating Tablet Sales Others , by Region K Tons (2021-2026)
  • Table 441. South America Orally Disintegrating Tablet Sales, by Country K Tons (2021-2026)
  • Figure 65. South America Orally Disintegrating Tablet Share (%), by Country
  • Table 442. South America Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 443. South America Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 444. South America Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 445. South America Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 446. Brazil Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 447. Brazil Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 448. Brazil Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 449. Brazil Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 450. Argentina Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 451. Argentina Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 452. Argentina Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 453. Argentina Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 454. Rest of South America Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 455. Rest of South America Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 456. Rest of South America Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 457. Rest of South America Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 458. Asia Pacific Orally Disintegrating Tablet Sales, by Country K Tons (2021-2026)
  • Figure 66. Asia Pacific Orally Disintegrating Tablet Share (%), by Country
  • Table 459. Asia Pacific Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 460. Asia Pacific Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 461. Asia Pacific Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 462. Asia Pacific Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 463. China Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 464. China Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 465. China Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 466. China Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 467. Japan Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 468. Japan Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 469. Japan Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 470. Japan Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 471. India Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 472. India Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 473. India Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 474. India Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 475. South Korea Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 476. South Korea Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 477. South Korea Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 478. South Korea Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 479. Taiwan Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 480. Taiwan Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 481. Taiwan Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 482. Taiwan Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 483. Australia Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 484. Australia Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 485. Australia Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 486. Australia Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 487. Rest of Asia-Pacific Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 488. Rest of Asia-Pacific Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 489. Rest of Asia-Pacific Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 490. Rest of Asia-Pacific Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 491. Europe Orally Disintegrating Tablet Sales, by Country K Tons (2021-2026)
  • Figure 67. Europe Orally Disintegrating Tablet Share (%), by Country
  • Table 492. Europe Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 493. Europe Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 494. Europe Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 495. Europe Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 496. Germany Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 497. Germany Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 498. Germany Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 499. Germany Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 500. France Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 501. France Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 502. France Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 503. France Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 504. Italy Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 505. Italy Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 506. Italy Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 507. Italy Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 508. United Kingdom Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 509. United Kingdom Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 510. United Kingdom Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 511. United Kingdom Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 512. Netherlands Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 513. Netherlands Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 514. Netherlands Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 515. Netherlands Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 516. Rest of Europe Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 517. Rest of Europe Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 518. Rest of Europe Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 519. Rest of Europe Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 520. MEA Orally Disintegrating Tablet Sales, by Country K Tons (2021-2026)
  • Figure 68. MEA Orally Disintegrating Tablet Share (%), by Country
  • Table 521. MEA Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 522. MEA Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 523. MEA Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 524. MEA Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 525. Middle East Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 526. Middle East Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 527. Middle East Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 528. Middle East Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 529. Africa Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 530. Africa Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 531. Africa Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 532. Africa Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 533. North America Orally Disintegrating Tablet Sales, by Country K Tons (2021-2026)
  • Figure 69. North America Orally Disintegrating Tablet Share (%), by Country
  • Table 534. North America Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 535. North America Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 536. North America Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 537. North America Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 538. United States Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 539. United States Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 540. United States Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 541. United States Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 542. Canada Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 543. Canada Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 544. Canada Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 545. Canada Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 546. Mexico Orally Disintegrating Tablet Sales, by Distribution Channel K Tons (2021-2026)
  • Table 547. Mexico Orally Disintegrating Tablet Sales, by Manufacturing Technique K Tons (2021-2026)
  • Table 548. Mexico Orally Disintegrating Tablet Sales, by Drug Class K Tons (2021-2026)
  • Table 549. Mexico Orally Disintegrating Tablet Sales, by Disease Indication K Tons (2021-2026)
  • Table 550. Research Programs/Design for This Report
  • Table 551. Key Data Information from Secondary Sources
  • Table 552. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Janssen Pharmaceutica (Belgium) Revenue, Net Income and Gross profit
  • Figure 27. Janssen Pharmaceutica (Belgium) Revenue: by Geography 2020
  • Figure 28. Schering plough Corp., USA (United States) Revenue, Net Income and Gross profit
  • Figure 29. Schering plough Corp., USA (United States) Revenue: by Geography 2020
  • Figure 30. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 32. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 34. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 36. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer (United States) Revenue: by Geography 2020
  • Figure 38. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 40. Eli Lilly Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 41. Eli Lilly Pharma (United States) Revenue: by Geography 2020
  • Figure 42. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 43. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 44. Ranbaxy Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 45. Ranbaxy Laboratories (India) Revenue: by Geography 2020
  • Figure 46. Astra Zeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 47. Astra Zeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 48. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 49. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 50. Zota Pharma (India) Revenue, Net Income and Gross profit
  • Figure 51. Zota Pharma (India) Revenue: by Geography 2020
List of companies from research coverage that are profiled in the study
  • Janssen Pharmaceutica (Belgium)
  • Schering plough Corp., USA (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Pfizer (United States)
  • Merck & Co. (United States)
  • Eli Lilly Pharma (United States)
  • GlaxoSmithKline (United Kingdom)
  • Ranbaxy Laboratories (India)
  • Astra Zeneca (United Kingdom)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Zota Pharma (India)
Additional players considered in the study are as follows:
Torrent Group (India) , Mylan N.V. (United States) , F. Hoffmann-La Roche Ltd. (Switzerland) , Bausch Health (Canada) , Sun Pharmaceutical Industries Ltd. (India) , Dr. Reddy’s Laboratories Ltd (India) , Eisai Co., Ltd. (Japan) , NEOS Therapeutics, Inc. (Switzerland) , Glenmark Pharmaceuticals (India) , Unichem Laboratories (India)
Select User Access Type

Key Highlights of Report


Sep 2021 234 Pages 77 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Orally Disintegrating Tablet Quantitative research analysis
Global Orally Disintegrating Tablet Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Orally Disintegrating Tablet study can be customized to meet your requirements. The market size breakdown by type [], by end use application [].
The Orally Disintegrating Tablet Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Orally Disintegrating Tablet market is expected to see growth rate of 10.7%.

Know More About Global Orally Disintegrating Tablet Report?

Have a Query? Click Here

Other Related Reports

Porcine Epidemic Diarrhea Vaccines Comprehensive Study by Type (Live, Killed), Application (Adult Pigs, Piglets), End Users (Veterinary Hospitals, Hog Production Farm) Players and Region - Global Mar...
$ 3500
Medical Cannabis Comprehensive Study by Active Ingredients (Tetrahydrocannabinol {THC}, Cannabidiol {CBD}), Point of Sale (Dispensaries, Online Pharmacy, Hospital Pharmacy), Therapeutic Application (...
$ 3650
Dementia Drugs Comprehensive Study by Type (MAO Inhibitors, Cholinesterase Inhibitors, Glutamate Inhibitors), Application (Hospital, Clinics, Others), Indication (Lewy Body Dementia, Parkinsons Disea...
$ 3650
Liposome Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphotericin B, Liposomal Paclitaxel), Application (Pharmaceutical, Cosmetic, Food, Farming), Therapy (Fungal Infe...
$ 3350
Anti-infective Agents Comprehensive Study by Type (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Application (Hospital Use, Clinic Use, Household, Other), Drug Type (Penicillins, Sulfonami...
$ 3750
Legal Marijuana Comprehensive Study by Type (Indoor, Greenhouse), Application (Chronic Pain, Mental Disorders, Cancer, Others), End-Users (Healthcare Industry, Recreational Industry, Others) Players ...
$ 3500